Preclinical evaluation of a cross-protective ß-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59
Joseph Torresi(The University of Melbourne), William R. Heath(Peter Doherty Institute), Chee Wah Tan(Duke-NUS Medical School), Daniel Fernandez‐Ruiz(UNSW Sydney), Julio Montoya(Universidad de Zaragoza), Lauren E. Holz(The University of Melbourne), Linda Earnest(The University of Melbourne), Melissa A. Edeling(The University of Melbourne), Lin‐Fa Wang(Beijing Institute of Technology), Jamie Mumford(Duke-NUS Medical School), Elizabeth Vincan(The University of Melbourne), Marc Pellegrini(The University of Melbourne), Steve Rockman(The University of Melbourne), Dale I. Godfrey(Peter Doherty Institute), Kanta Subbarao(Peter Doherty Institute), James P. Cooney(The University of Melbourne), Danielle E. Anderson(Peter Doherty Institute), Dhiraj Hans(International Centre for Genetic Engineering and Biotechnology), Stéphanie Gras(La Trobe University), Ashley Huey Yiing Yap(The University of Melbourne), Jason Roberts(The University of Queensland), Simon Collett(The University of Melbourne), Chinn Yi Wong(The University of Melbourne), Kathryn Davidson(University of Florida)
Cited by 2
Related Papers
Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2
|The EMBO Journal|2020|499
Identification of phenotypically and functionally heterogeneous mouse mucosal-associated invariant T cells using MR1 tetramers
|The Journal of Experimental Medicine|2015|381